Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Gynecologic 2Genitourinary 2Thoracic 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 486Glioma 228Glioblastoma 224Neoplasms 62Neuroblastoma 56Central Nervous System Neoplasms 56Breast Neoplasms 54Meningioma 48Astrocytoma 43Neuroma, Acoustic 38Spinal Cord Neoplasms 35Neurofibromatosis 1 32Sarcoma 29Oligodendroglioma 29Lung Neoplasms 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Neoplasm Metastasis 26Head and Neck Neoplasms 25Melanoma 22Lymphoma, Non-Hodgkin 22Leukemia 22Meningeal Carcinomatosis 21Medulloblastoma 21Hodgkin Disease 21Burkitt Lymphoma 20Testicular Neoplasms 19Lymphoma, Follicular 19Multiple Myeloma 18Gliosarcoma 18

Interventions

Sufentanil 1((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Postoperative Nausea and Vomiting × CNS × Clear all
NCT07479446 2026-05-22

Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery

Xuanwu Hospital, Beijing

Phase NA Recruiting
174 enrolled
CNS

Neuroma, Acoustic, Postoperative Nausea and Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡